You are here: Industry Insights > immunotherapy

News List

Rare melanoma type highly responsive to immunotherapy europeanpharmaceuticalreview
April 30, 2019
Moffitt Cancer Center researchers have discovered that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed.
Combination immunotherapy improves survival in mouse models of mesothelioma europeanpharmaceuticalreview
April 28, 2019
Combined treatment with two cancer immunotherapy drugs significantly prolonged survival in aggressive cancer malignant mesothelioma…
Immunotherapy drug could boost hormone treatment for prostate cancer europeanpharmaceuticalreview
April 22, 2019
Researchers believe the combination with established treatment could improve outcomes in prostate cancer…
Researchers develop new vaccine to teach immune system to attack cancer pharmaceutical-technology
April 11, 2019
Researchers develop new vaccine to teach immune system to attack cancer.
WindMIL Therapeutics Announces Key Appointment contractpharma
March 27, 2019
WindMIL Therapeutics has announced the appointment of Sanjin Zvonić, PhD, as vice president of Process Science and Manufacturing.
Setback for Allergy’s birch pollen immunotherapy drugs
March 19, 2019
Shares in UK-based Allergy Therapeutics have taken a dive after the firm’s immunotherapy for birch pollen allergy failed to hit targets in a late-stage trial.
Hematogenix Launches FDA Approved Companion Diagnostic Immuno-oncology Test for Triple-Negative Breast Cancer en-cphi.cn
March 13, 2019
Hematogenix® announced the launch of the companion diagnostic test for the drug TECENTRIQ®. On March 8, 2019.
Inovio Initiates REVEAL 2 Global Phase 3 Clinical Study For the Treatment of HPV-Related Cervical Pre-cancer en-cphi.cn
March 07, 2019
The second Phase 3 study initiation announcement made during the International HPV Awareness Day
NantKwest and ProMab partner to develop NK cell therapies pharmaceutical-technology
March 06, 2019
Immunotherapy company NantKwest has partnered with ProMab Biotechnologies with the aim of developing a select next generation targeted natural killer (NK) cell therapy.
Merck agrees to acquire Immune Design for $300m pharmaceutical-technology
February 26, 2019
Merck has reached an agreement to acquire all outstanding shares of US-based late-stage immunotherapy firm Immune Design in an all cash deal valued at approximately $300m, or $5.85 per share....

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page